

1/12/06

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10810649-2.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:40:56 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1731 TO ITERATE

100.0% PROCESSED 1731 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 32125 TO 37115

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

10810649

1/12/06

=> s l1 ful

FULL SEARCH INITIATED 14:41:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 34394 TO ITERATE

100.0% PROCESSED 34394 ITERATIONS
SEARCH TIME: 00.00.01

3 ANSWERS

L3 3 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 14:41:09 ON 12 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jan 2006 VOL 144 ISS 3
FILE LAST UPDATED: 11 Jan 2006 (20060111/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s l3

L4 2 L3

=> d abs fbib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
GI



10810649

1/12/06

AB Novel polyamines, their synthesis and use in pharmacol., cosmetic or agricultural applications are provided. Novel polyamines having the structure (I) [wherein, n = 0-8; the aminomethyl functionality can be ortho, meta or para substituted; R = H, Me, Et, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl, N-ethyl-8-aminooctyl; R1 = H, straight or branched C1-20 (un)saturated aliphatic, aliphatic amine (except for propylamine when R = H, n=1 and the aminomethyl functionality is para substituted), alicyclic group, single or multi-ring aromatic group, single or multi-ring aryl substituted aliphatic group, aliphatic-substituted single or multi-ring aromatic group, single or multi-ring heterocyclyl, single or multi-ring heterocyclic-substituted aliphatic, aliphatic-substituted aromatic group, halogenated forms thereof; wherein said polyamine is a non-sym. xylene] are prepared. Also provided are the use of the polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of polyamines

by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used as fungal, bacterial, viral and parasitic agents or to treat any disease associated with cellular proliferation including cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease, and other inflammatory bowel diseases. A series of compds. I were screened for their ability to induce frameshifting using the dual luciferase reporter assay in HEK-293 cells. Some of these compds. induced frameshifting substantially better than spermidine. For example, compound (II) showed the percent relative frameshifting value (% RF) of 150% compared to 25 μ M spermidine.

AN 2004:878166 CAPLUS

DN 141:366226

TI Preparation of polyamine analogs that activate antizyme frameshifting

IN Burns, Mark R.; Graminski, Gerard F.

PA Mediquest Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 251,819.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819	A2 20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

PATENT FAMILY INFORMATION:

FAN 2004:252193

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923

10810649

1/12/06

US 6914079 B2 20050705
US 2004209926 A1 20041021 US 2004-810649 20040329
US 2002-251819 A2 20020923
WO 2005105729 A1 20051110 WO 2004-US9582 20040329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG


US 2002-251819 A 20020923

OS MARPAT 141:366226

IT 673461-33-1P, 1-Aminomethyl-4-(10-amino-2,7-diazadecyl)benzene
778831-92-8P, 1-Aminomethyl-4-(11-amino-2,7-diazaundecyl)benzene
778831-98-4P, 1-Aminomethyl-4-(12-amino-2,7-diazadodecyl)benzene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of polyamine analogs as activating agents for antizyme
frameshifting to treat diseases associated with cellular proliferation or
as antifungal, antibacterial, antiviral and antiparasitic agents)


RN 673461-33-1 CAPLUS

CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA
INDEX NAME)



RN 778831-92-8 CAPLUS


CN 1,4-Benzenedimethanamine, N-[4-[(4-aminobutyl)amino]butyl]- (9CI) (CA
INDEX NAME)



RN 778831-98-4 CAPLUS

CN 1,4-Benzenedimethanamine, N-[4-[(5-aminopentyl)amino]butyl]- (9CI) (CA
INDEX NAME)

1/12/06



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AB The invention provides synthesis and use of polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used to treat any disease associated with cellular proliferation including but not limited to cancer. As such, they will be useful as drugs to treat diseases where components of the immune system undergo undesired proliferation. The compds. will also be effective for the treatment of unwanted proliferation of hair or skin. The invention also identifies key structural elements expected to comprise the antizyme inducing motifs of small mols. related to polyamines.

AN 2004:252193 CAPLUS

DN 140:264534

TI Polyamine analogs that activate antizyme framshifting

IN Burns, Mark R.; Graminski, Gerard F.

PA Mediquest Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 29 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		
	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819	A2 20020923
WO	2005105729	A1	20051110	WO 2004-US9582	20040329
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2002-251819 A 20020923

PATENT FAMILY INFORMATION:


FAN 2004:878166

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819	A2 20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

10810649

1/12/06

OS MARPAT 140:264534
IT 673461-33-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(polyamine analogs that activate antizyme framshifting)
RN 673461-33-1 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA
INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

1/12/06

CT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information.  *
*
*****
```


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10810649-3.str



chain nodes :

7 8 9 10 11 12 18 19 20 21 22 23 24 25 26 27

ring nodes :

1 2 3 4 5 6

chain bonds :

1-9 2-23 3-22 4-7 5-21 6-20 7-8 7-18 7-19 9-10 10-27 11-12 11-24 24-26
24-25 24-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

7-8 24-26

exact bonds :

1-9 2-23 3-22 4-7 5-21 6-20 7-18 7-19 9-10 10-27 11-12 11-24 24-25
24-27

10810649

1/12/06

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
24:CLASS 25:CLASS
26:CLASS 27:CLASS

L6 STRUCTURE UPLOADED

=> s l6
SAMPLE SEARCH INITIATED 17:25:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 53297 TO ITERATE

3.8% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1052176 TO 1079704
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s l6 ful
FULL SEARCH INITIATED 17:25:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1053005 TO ITERATE

95.0% PROCESSED 1000000 ITERATIONS 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1053005 TO 1053005
PROJECTED ANSWERS: 5 TO 11


L8 5 SEA SSS FUL L6

=> d scan

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1,4-Benzenedimethanamine, N-(3-aminopropyl)- (9CI)
MF C11 H19 N3

10810649

1/12/06




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2-5
'2-5' IS NOT VALID HERE


To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 2,5-difluoro-4-hydrazino- (9CI)
MF C7 H9 F2 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 3-chloro-4-hydrazino- (9CI)
MF C7 H10 Cl N3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 4-hydrazino-3-nitro- (9CI)
MF C7 H10 N4 O2


10810649

1/12/06



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 4-hydrazino-3-(trifluoromethyl) - (9CI)
MF C8 H10 F3 N3





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\Stnexp\Queries\10810649-3.str



10810649

1/12/06

chain nodes :

7 8 9 10 11 12 18 19 20 21 22 23 24 25 26 27

ring nodes :

1 2 3 4 5 6

chain bonds :

1-9 2-23 3-22 4-7 5-21 6-20 7-8 7-18 7-19 9-10 10-27 11-12 11-24 24-26

24-25 24-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

7-8 24-26

exact bonds :

1-9 2-23 3-22 4-7 5-21 6-20 7-18 7-19 9-10 10-27 11-12 11-24 24-25

24-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 12:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS

24:CLASS 25:CLASS

26:CLASS 27:CLASS

L9 STRUCTURE UPLOADED


=> d l9

L9 HAS NO ANSWERS

L9 STR

10810649

1/12/06



Structure attributes must be viewed using STN Express query preparation.

=> s l9

SAMPLE SEARCH INITIATED 17:29:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 53341 TO ITERATE

3.7% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1053050 TO 1080590
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s l9 ful

FULL SEARCH INITIATED 17:29:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1054250 TO ITERATE

94.9% PROCESSED 1000000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.12

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1054250 TO 1054250
PROJECTED ANSWERS: 3 TO 8

10810649

1/12/06

L11 3 SEA SSS FUL L9

=> d scan 1-3


'1-3' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L11 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Guanidine, N-[(4S)-4-amino-5-[[4-(aminomethyl)phenyl]amino]pentyl]-N'-nitro- (9CI)

MF C13 H23 N7 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO

10810649

1/12/06

STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels

IBIB -- BIB, indented, with text labels

ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.

HELP FORMATS -- To see detailed descriptions of the predefined formats.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L11 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


IN L-Leucine, N2-[[4-(aminomethyl)phenyl]methyl]-L-lysyl-L-seryl-L-phenylalanyl-ψ(CH₂-NH)- (9CI)

SQL 4

MF C32 H50 N6 O5

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



L11 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN L-Serinamide, N2-[[4-(aminomethyl)phenyl]methyl]-L-lysyl-N-[[4-[[[(1S)-1-carboxy-3-methylbutyl]amino]methyl]phenyl]methyl]- (9CI)

SQL 4

10810649


1/12/06

MF C31 H48 N6 O5

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH₂

ALL ANSWERS HAVE BEEN SCANNED

10810649

1/12/06

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:40:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1731 TO ITERATE

100.0% PROCESSED 1731 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 32125 TO 37115
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 14:41:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 34394 TO ITERATE

100.0% PROCESSED 34394 ITERATIONS 3 ANSWERS

10810649

1/12/06

SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 14:41:09 ON 12 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jan 2006 VOL 144 ISS 3

FILE LAST UPDATED: 11 Jan 2006 (20060111/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s l3

L4 2 L3

=> d abs fbib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

GI



AB Novel polyamines, their synthesis and use in pharmacol., cosmetic or agricultural applications are provided. Novel polyamines having the

10810649

1/12/06

structure (I) [wherein, n = 0-8; the aminomethyl functionality can be ortho, meta or para substituted; R = H, Me, Et, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminoethyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentyl, N-methyl-6-aminoethyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminoethyl, N-ethyl-7-aminoheptyl, N-ethyl-8-aminooctyl; R1 = H, straight or branched C1-20 (un)saturated aliphatic, aliphatic amine (except for propylamine when R = H, n=1 and the aminomethyl functionality is para substituted), alicyclic group, single or multi-ring aromatic group, single or multi-ring aryl substituted aliphatic group, aliphatic-substituted single or multi-ring aromatic group, single or multi-ring heterocyclyl, single or multi-ring heterocyclic-substituted aliphatic, aliphatic-substituted aromatic group, halogenated forms thereof; wherein said polyamine is a non-sym. xylene] are prepared Also provided are the use of the polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of

polyamines

by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used as fungal, bacterial, viral and parasitic agents or to treat any disease associated with cellular proliferation including cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restenosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease, and other inflammatory bowel diseases. A series of compds. I were screened for their ability to induce frameshifting using the dual luciferase reporter assay in HEK-293 cells. Some of these compds. induced frameshifting substantially better than spermidine. For example, compound (II) showed the percent relative frameshifting value (% RF) of 150% compared to 25 µM spermidine.

AN 2004:878166 CAPLUS

DN 141:366226

TI Preparation of polyamine analogs that activate antizyme frameshifting

IN Burns, Mark R.; Graminski, Gerard F.

PA Mediquest Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 251,819.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819	A2 20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

PATENT FAMILY INFORMATION:

FAN 2004:252193

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		
	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819	A2 20020923

10810649

1/12/06

WO 2005105729 A1 20051110 WO 2004-US9582 20040329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 2002-251819 A 20020923

OS MARPAT 141:366226

IT 673461-33-1P, 1-Aminomethyl-4-(10-amino-2,7-diazadecyl)benzene

778831-92-8P, 1-Aminomethyl-4-(11-amino-2,7-diazaundecyl)benzene


778831-98-4P, 1-Aminomethyl-4-(12-amino-2,7-diazadodecyl)benzene

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of polyamine analogs as activating agents for antizyme
frameshifting to treat diseases associated with cellular proliferation or
as antifungal, antibacterial, antiviral and antiparasitic agents)


RN 673461-33-1 CAPLUS

CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA
INDEX NAME)




RN 778831-92-8 CAPLUS

CN 1,4-Benzenedimethanamine, N-[4-[(4-aminobutyl)amino]butyl]- (9CI) (CA
INDEX NAME)



RN 778831-98-4 CAPLUS

CN 1,4-Benzenedimethanamine, N-[4-[(5-aminopentyl)amino]butyl]- (9CI) (CA
INDEX NAME)



10810649

1/12/06

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AB The invention provides synthesis and use of polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used to treat any disease associated with cellular proliferation including but not limited to cancer. As such, they will be useful as drugs to treat diseases where components of the immune system undergo undesired proliferation. The compds. will also be effective for the treatment of unwanted proliferation of hair or skin. The invention also identifies key structural elements expected to comprise the antizyme inducing motifs of small mols. related to polyamines.

AN 2004:252193 CAPLUS

DN 140:264534

TI Polyamine analogs that activate antizyme framshifting

IN Burns, Mark R.; Graminski, Gerard F.

PA Mediquest Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 29 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		
	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819	A2 20020923
WO	2005105729	A1	20051110	WO 2004-US9582	20040329
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-251819	A 20020923

PATENT FAMILY INFORMATION:

FAN 2004:878166

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819	A2 20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

OS MARPAT 140:264534

IT 673461-33-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(polyamine analogs that activate antizyme framshifting)

10810649

1/12/06

RN 673461-33-1 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA
INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
24.68	191.83

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-1.50

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:42:23 ON 12 JAN 2006

Connecting via Winsock to STN